Ambeed.cn

首页 / / / / Cisapride/西沙必利

Cisapride/西沙必利 {[allProObj[0].p_purity_real_show]}

货号:A238567 同义名: 西沙比利 / (±)-Cisaprid; R 51619

Cisapride是一种 5-HT4 受体激动剂,IC50 为 9.4 nM,具有胃促动力作用,能刺激肠道释放乙酰胆碱。

Cisapride/西沙必利 化学结构 CAS号:81098-60-4
Cisapride/西沙必利 化学结构
CAS号:81098-60-4
Cisapride/西沙必利 3D分子结构
CAS号:81098-60-4
Cisapride/西沙必利 化学结构 CAS号:81098-60-4
Cisapride/西沙必利 3D分子结构 CAS号:81098-60-4
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Cisapride/西沙必利 纯度/质量文件 产品仅供科研

货号:A238567 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
Cell, 2025. Ambeed. [ A122167 ]
Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >
产品名称 5-HT 5-HT1 5-HT2 5-HT3 5-HT5 5-HT6 5-HT7 其他靶点 纯度
Desvenlafaxine ++

5-HT, Ki: 40.2 nM

98%
Lamotrigine +

5-HT (human platelets), IC50: 240 μM

5-HT (rat brain synaptosomes), IC50: 474 μM

98%
Venlafaxine 99%
Fluvoxamine maleate 99%
Iloperidone 99%
Ziprasidone HCl 98+%
Atomoxetine HCI +

5-HT, Ki: 77 nM

98%
Dapoxetine HCl 97%
Trazodone 98+%
Clomipramine HCl 98%
Mirtazapine 99+%
Escitalopram oxalate +++

5-HT, Ki: 0.89 nM

97%
Duloxetine 97%
Sertraline HCl ++

5-HT, Ki: 13 nM

98%
Citalopram HBr +++

serotonin reuptake, IC50: 1.8 nM

98%
Latrepirdine 2HCl GluR 99%
Fluoxetine HCl 99.5%
Paroxetine HCl AChR 99%
BMY 7378 ++

5-HT1D, pIC50: 5.9

5-HT1A, pIC50: 6.4

+

5-HT2, pIC50: 5.5

97%
Flibanserin +++

5-HT1A, Ki: 1 nM

+

5-HT2A, Ki: 49 nM

95%
LY310762 +

5-HT1D, Ki: 249 nM

99%+
Cyclobenzaprine HCI 99%
Blonanserin +++

5-HT2, Ki: 3.98 nM

99%
Cyproheptadine HCl ++++

5-HT2, IC50: 0.6 nM

99+%
Olanzapine 99+%
Pimavanserin hemitartrate +++

5-HT2A, pIC50: 8.7

99%
Ketanserin +++

5-HT2C (Human), Ki: 2.5 nM

5-HT2C (Rat), Ki: 50 nM

99%+
Loxapine succinate ++

5-HT2 (bovine), Ki: 6.6 nM

5-HT2 (human), Ki: 6.8 nM

98%
Agomelatine 98%
Clozapine 98%
Amitriptyline +

5-HT2, Ki: 235 nM

SERT 99%
PRX-08066 maleate +++

5-HT2B, IC50: 3.4 nM

98+%
RS-127445 ++++

5-HT2B, pIC50: 10.4

5-HT2B, pKi: 9.5

99%+
Sarpogrelate HCl ++++

5-HT2A, Kd: 2.1 nM

5-HT2C, Kd: 1.1 nM

98%
Tropisetron 99%
Ramosetron HCl ++++

5-HT3 receptor, Ki: 0.091 nM

98%
Ondansetron 99%
Granisetron 98%
Alosetron HCl 98%
Ondansetron HCl dihydrate 98%
VUF10166 ++++

5-HT3A, Ki: 0.04 nM

5-HT3AB, Ki: 22 nM

99%+
Azasetron HCl ++++

5-HT3, IC50: 0.33 nM

99%
Asenapine maleate +++

5-HT1B, pKi: 8.4

5-HT1A, pKi: 8.6

++++

5-HT2C, pKi: 10.46

5-HT2A, pKi: 9.75

+++

5-HT5A, pKi: 8.84

++++

5-HT6, pKi: 9.6

++++

5-HT7, pKi: 9.94

97%
Risperidone ++

5-HT1D, Ki: 84.6 nM

5-HT1B, Ki: 14.9 nM

++++

5-HT2C, Ki: 12 nM

5-HT2A, Ki: 61.9 nM

+

5-HT5A, Ki: 206 nM

++

5-HT7, Ki: 6.6 nM

98%
SB 271046 HCl +++

5-HT6, pKi: 8.92

99%+
Intepirdine ++++

5-HT6, pKi: 9.63

99%+
SB-269970 HCl ++

5-HT7, pKi: 8.3

98+%
BRL 15572 ++

5-HT1B, pKi: 6.1

5-HT1D, pKi: 6

++

5-HT2B, pKi: 6.2

5-HT2A, pKi: 6.6

+

5-HT6, pKi: 5.9

+

5-HT7, pKi: 6.3

95%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Cisapride/西沙必利 生物活性

描述 Cisapride (R 51619) is an orally active 5-HT4 receptor agonist with an EC50 value of 140 nM. Cisapride is also an hERG blocker with an IC50 value of 9.4 nM. It functions as a gastroprokinetic agent, stimulating gastrointestinal motor activity[1][2][3][4].
体内研究

Cisapride (0.1-1 mg/kg; i.v., once) enhances antral and colonic motility in conscious dogs[3].

Cisapride (2 mg/kg (i.p.); 4 mg/kg, (oral administration); once) does not exhibit significant differences in macroscopic features, histopathological features, cytokine profile, or bodyweight changes compared to TNBS-treated rats[4].

体外研究

Cisapride (1-100 nM) exhibits potent hERG blockade with an IC50 value of 9.4 nM[1].

Cisapride (1-100 nM) demonstrates efficacy at the 5-HT4 receptor with an EC50 value of 140 nM[1].

Cisapride demonstrates dose-dependent inhibition of Kv4.3 potassium channels expressing CHO cells, with an IC50 value of 9.8 μM, across concentrations of 0.3, 1, 3, 10, and 30 μM[2].

Cisapride/西沙必利 细胞实验

Cell Line
Concentration Treated Time Description References
human liver microsomes 5 μM 30 min To investigate the metabolism pathways and major metabolites of cisapride. Results showed that cisapride is primarily metabolized by CYP3A4, forming the major metabolite norcisapride. Br J Pharmacol. 2000 Apr;129(8):1655-67
Rat proximal colon mucosa-submucosa or mucosa-only preparations 100 μM To investigate the effects of luminal 5-HT on colonic anion secretion, it was found that luminal 5-HT increased HCO3− secretion via 5-HT4 receptor activation, and was not affected by TTX or atropine. Br J Pharmacol. 2015 Oct;172(19):4655-70
HEK293 cells 19.5, 39.1, 156, 313, 625, 1250, 2500, 5000, 10000, 20000 nM Evaluate the inhibitory effect of Cisapride on hERG channels, IC50 value was 938 nM Br J Pharmacol. 2016 Oct;173(19):2819-32
HEK293 cells 0.1, 0.3, 1, 3, 10, 30, 100 nM Evaluate the inhibitory effect of Cisapride on hERG channels, IC50 value was 6.8 nM Br J Pharmacol. 2016 Oct;173(19):2819-32
iPSC-derived cardiomyocytes 0.1 μM, 1 μM, 10 μM, 100 μM 24 h To evaluate the effects of cisapride on calcium flux and QT prolongation in cardiomyocytes. Results showed that cisapride induced changes in calcium flux, manifested as QT prolongation, with some cells exhibiting Torsade's-like arrhythmias. ALTEX. 2018;35(4):441-452
Oocytes expressing HERG channels 0.133 µM To study the blocking effect of Cisapride on HERG channels, showing an IC50 of 0.133 µM. Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12329-33

Cisapride/西沙必利 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00699894 Postoperative Nausea and Vomit... 展开 >>ing 收起 << Not Applicable Withdrawn(Logistical difficult... 展开 >>ies running the study) 收起 << - United States, New York ... 展开 >> Long Island Jewish Medical Center/Schneider's Children Hospital New Hyde Park, New York, United States, 11040 收起 <<
NCT02524496 - Completed - -
NCT01281540 Gastroparesis Phase 4 Terminated(Sponsor request) - -

Cisapride/西沙必利 参考文献

[1]Toga, T., Y. Kohmura, and R. Kawatsu, The 5-HT(4) agonists cisapride, mosapride, and CJ-033466, a Novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities. J Pharmacol Sci, 2007. 105(2): p. 207-10.

[2]Sung, K.W. and S.J. Hahn, Effect of mosapride on Kv4.3 potassium channels expressed in CHO cells. Naunyn Schmiedebergs Arch Pharmacol, 2013. 386(10): p. 905-16.

[3]Mine, Y, et al. Comparison of effect of mosapride citrate and existing 5-HT4 receptor agonists on gastrointestinal motility in vivo and in vitro. J Pharmacol Exp Ther, 1997. 283(3): p. 1000-8.

[4]Motavallian, A, et al., Does Cisapride, as a 5HT(4) Receptor Agonist, Aggravate the Severity of TNBS-Induced Colitis in Rat. Gastroenterol Res Pract, 2012. 2012: p. 362536.

Cisapride/西沙必利 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.15mL

0.43mL

0.21mL

10.73mL

2.15mL

1.07mL

21.46mL

4.29mL

2.15mL

Cisapride/西沙必利 技术信息

CAS号81098-60-4
分子式C23H29ClFN3O4
分子量 465.95
SMILES Code O=C(C1=CC(Cl)=C(C=C1OC)N)N[C@@H]2[C@@H](CN(CC2)CCCOC3=CC=C(C=C3)F)OC
MDL No. MFCD00869327
别名 西沙比利 ;(±)-Cisaprid; R 51619; Propulsid; Pridesia; Presid; Prepulsid; Kinestase; Kaudalit
运输蓝冰
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Sealed in dry,2-8°C

溶解方案

DMSO: 105 mg/mL(225.35 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
方案 一
方案 二
AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。